Menu
Recruiting NCT07315295

Maximizing the Benefits of Iron in Ready-to-Use Therapeutic Foods for Malnourished Children in Kenya

No phase Interventional Iron Absorption Iron Deficiencies Severly Acutely Malnourished Children Malnutrition in Children

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Iron absorption from RUTF on Day 0, Treatment with RUTF for 80 days, Iron absorption from RUTF on Day 20, Iron absorption from RUTF on Day 40.
Who it may be relevant to
Registry conditions: Iron Absorption, Iron Deficiencies, Severly Acutely Malnourished Children, Malnutrition in Children. Basic parameters: 12 months — 54 months · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Kenya, Switzerland
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Maximizing the Benefits of Iron in Ready-to-use Therapeutic Foods for Malnourished Children in Kenya

Overview

Reports from the Kenya Red Cross Society (KRCS) in Kwale County, southern Kenya, indicate a limited impact of Ready-to-Use Therapeutic Foods (RUTFs) on malnutrition or anemia. The current RUTF formulation may have an excessively high iron content. In severely acutely malnourished (SAM) children, iron cannot be properly absorbed, leading to life-threatening diarrhea. The overall aim of this project is to develop an improved RUTF treatment that addresses acute malnutrition and anemia in children, ensuring both safety and efficacy. Specifically, to assess the impact of malnutrition on fractional iron absorption (FIA) from RUTFs in children, by comparing healthy children to those with acute malnutrition and by tracking changes in FIA in malnourished children over the course of treatment.

Interventions

  • Other Iron absorption from RUTF on Day 0
    RUFT with 57Fe
  • Dietary supplement Treatment with RUTF for 80 days
    Daily RUTF intake
  • Other Iron absorption from RUTF on Day 20
    RUFT with 57Fe
  • Other Iron absorption from RUTF on Day 40
    RUFT with 57Fe
  • Other Iron absorption from RUTF on Day 60
    RUFT with 57Fe

Primary outcome measures

  • Fractional Iron Absorption [Time frame: Day 0]
  • Fractional Iron Absorption [Time frame: Day 20]
  • Fractional Iron Absorption [Time frame: Day 40]
  • Fractional Iron Absorption [Time frame: Day 60]
Secondary outcome measures (12)
  • Hemoglobin [Time frame: Day 0]
  • Hemoglobin [Time frame: Day 20]
  • Hemoglobin [Time frame: Day 40]
  • Hemoglobin [Time frame: Day 60]
  • Hemoglobin [Time frame: Day 80]
  • Serum ferritin [Time frame: Day 0]
  • Serum Ferritin [Time frame: Day 20]
  • Serum Ferritin [Time frame: Day 40]
  • Serum Ferritin [Time frame: Day 60]
  • soluble transferrin receptor [Time frame: Day 0]
  • soluble transferrin receptor [Time frame: Day 20]
  • soluble transferrin receptor [Time frame: Day 40]

Eligibility criteria

Inclusion criteria

malnourished children:

  • severe acute malnutrition (SAM): WHZ < -3.0
  • moderate acute malnutrition (MAM): WHZ < -2.0 a
  • treated as outpatients (no acute medical conditions and a positive appetite test)

healthy children:

\- healthy: HAZ, WAZ and WHZ = 0

Exclusion Criteria (both groups):

  • Hemoglobin ≤7 g/dL
  • Presence of acute medical conditions requiring inpatient management

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
N/A
Model
Parallel assignment
Masking
Open label
Primary purpose
Other

Study locations

Kenya · 1 center
  • ETH/Oxford/JKUAT research facility — Msambweni
Switzerland · 1 center
  • ETH Zurich, Laboratory of Clinical Biopharmacy, Zurich, 8092 — Zurich

Identifiers

NCT: NCT07315295 · SAMI

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗